Persistent URL of this record https://hdl.handle.net/1887/94534
In Collections
This item can be found in the following collections:
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial
- All authors
- Kim, Y.H.; Bagot, M.; Pinter-Brown, L.; Rook, A.H.; Porcu, P.; Horwitz, S.M.; Whittaker, S.; Tokura, Y.; Vermeer, M.; Zinzani, P.L.; Sokol, L.; Morris, S.; Kim, E.J.; Ortiz-Romero, P.L.; Eradat, H.; Scarisbrick, J.; Tsianakas, A.; Elmets, C.; Dalle, S.; Fisher, D.C.; Halwani, A.; Poligone, B.; Greer, J.; Fierro, M.T.; Khot, A.; Moskowitz, A.J.; Musiek, A.; Shustov, A.; Pro, B.; Geskin, L.J.; Dwyer, K.; Moriya, J.; Leoni, M.; Humphrey, J.S.; Hudgens, S.; Grebennik, D.O.; Tobinai, K.; Duvic, M.; MAVORIC Investigators
- Date
- 2018-09-30
- Journal
- The Lancet Oncology
- Volume
- 19
- Issue
- 9
- Pages
- 1192 - 1204